Designing Amorphous Dispersion Formulations for Poorly Soluble Drugs

Many orally administered small molecules have low aqueous solubility, which leads to poor oral absorption. For many of these poorly soluble drugs currently in development, amorphous dispersions are increasingly being used as a formulation approach to improve solubility and oral absorption.
Watch Now

Spotlight

OTHER ON-DEMAND WEBINARS

Sustainable Sourcing & Supply Chain Engagement in Pharma

BASF

Various aspects of the pharma sourcing process and supplier relationships offer opportunities to advance sustainability and strategic goals. These include alternative raw materials at manufacturing facilities (e.g., biomass and recycled plastic), sourcing of renewable materials (e.g., palm oil), partnering on supplier sustainability, and more.For example, BASF has seen sustainable sourcing begin to matter more for pharma, with a number of pharma companies taking a proactive role, because:
Watch Now

Integrating Polygenic and Monogenic Germline Testing Results Into Prostate Cancer Risk Assessment

Ambry Genetics

In this webinar, Dr. Xu will summarize recent data on inherited risk for prostate cancer, including germline mutations in high-penetrance genes (HPGs), risk-associated SNPs, and SNP-based genetic risk score (GRS). He will present detailed data supporting the broad-sense validity of GRS in risk assessment as well as the need for assessing the narrow-sense validity of GRS values. Finally, he will review the data supporting the importance of GRS when estimating the penetrance of HPGs.
Watch Now

Successfully Digitalizing Drug Manufacturing

The COVID crisis has revealed the importance of rapid and optimized equipment design and scale up for drug and vaccine manufacturing processing as well as the necessity to maintain an optimal productivity level throughout the equipment lifecycle.
Watch Now

How to get speed and depth in your Host Cell Protein (HCP) analysis

Technology Networks

In the rapidly expanding arena of biotherapeutic analysis and bioprocess development, the analysis of host cell proteins (HCP) is transitioning to a new phase. HCPs are contaminants in biotherapeutic drug preparations, often at low ppm concentration levels, and must be monitored due to stability, efficacy and immunogenicity concerns. Often, these protein impurities will be considered Critical Quality Attributes (CQA) and can contribute to an overall risk assessment for the product.
Watch Now

Spotlight

resources